Literature DB >> 29037859

Chorionic Gonadotropin-β Modulates Epithelial-Mesenchymal Transition in Colorectal Carcinoma Metastasis.

Futoshi Kawamata1, Hiroshi Nishihara2, Shigenori Homma1, Yasutaka Kato3, Masumi Tsuda3, Yuji Konishi1, Lei Wang4, Shinji Kohsaka5, Cheng Liu6, Tadashi Yoshida1, Mishie Tanino3, Shinya Tanaka3, Hideki Kawamura1, Toshiya Kamiyama1, Akinobu Taketomi1.   

Abstract

Ectopic production of free β human chorionic gonadotropin (hCGβ) has been associated with aggressive behavior in non-trophoblastic tumors. hCGβ shares common evolutionary sequences with transforming growth factor-β (TGF-β), which represents a major driving force of epithelial-to-mesenchymal transition (EMT). In this study, we examined the biological roles of hCGβ during EMT and its clinical significance in colorectal cancer (CRC) progression. Eighty CRC specimens and 54 preoperative serum samples were analyzed. hCGβ-overexpressing human CRC cell lines were examined for invasiveness and tumorigenicity, and the expression of EMT-associated genes was investigated. In human CRC, histologic hCGβ positivity [13/80 (16.3%)] was lower than serologic hCGβ positivity [13/54 (24.1%)]. However, it was significantly correlated with several clinicopathological features and unfavorable outcome (P < 0.05). hCGβ-overexpressing cell lines had increased invasiveness, migratory ability, and metastatic potential in mice (P < 0.01). Western blot, PCR, and microarray analyses showed hCGβ altered expression of EMT-related genes, including E-cadherin, phosphorylated SMAD2, SNAIL, and TWIST. hCGβ-induced SNAIL and TWIST overexpression levels were reversible by type I and type II TGF-β receptor inhibitors (P < 0.05). hCGβ thus induces EMT via the TGF-β signaling pathway, and it may represent a molecular target in CRC treatment.
Copyright © 2018 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29037859     DOI: 10.1016/j.ajpath.2017.08.034

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  6 in total

1.  Human chorionic gonadotropin-β promotes pancreatic cancer progression via the epithelial mesenchymal transition signaling pathway.

Authors:  Yasunori Uesato; Futoshi Kawamata; Shinichiro Ishino; Shinichiro Ono; Koichi Tamashiro; Hirofumi Koyama; Mitsuhisa Takatsuki
Journal:  J Gastrointest Oncol       Date:  2022-06

2.  Ophthalmoplegia in a Her2+ and β-hCG+ Patient With Leptomeningeal Carcinomatosis Secondary to Gastric Adenocarcinoma.

Authors:  Zachary Falk; Mei Bou Nasif; Nabil Fallouh
Journal:  Cureus       Date:  2022-07-08

3.  Tumor budding and human chorionic gonadotropin-β expression correlate with unfavorable patient outcome in colorectal carcinoma.

Authors:  Yuji Konishi; Futoshi Kawamata; Hiroshi Nishihara; Shigenori Homma; Yasutaka Kato; Masumi Tsuda; Shinji Kohsaka; Takahiro Einama; Cheng Liu; Tadashi Yoshida; Akihisa Nagatsu; Mishie Tanino; Shinya Tanaka; Hideki Kawamura; Toshiya Kamiyama; Akinobu Taketomi
Journal:  Med Oncol       Date:  2018-06-11       Impact factor: 3.064

4.  Human Miscarriage Is Associated With Dysregulations in Peripheral Blood-Derived Myeloid Dendritic Cell Subsets.

Authors:  Stefanie Ehrentraut; Karoline Sauss; Romy Neumeister; Lydia Luley; Anika Oettel; Franziska Fettke; Serban-Dan Costa; Stefanie Langwisch; Ana Claudia Zenclussen; Anne Schumacher
Journal:  Front Immunol       Date:  2019-10-15       Impact factor: 7.561

5.  Human chorionic gonadotropin promotes murine Treg cells and restricts pregnancy-harmful proinflammatory Th17 responses.

Authors:  Lea S Lentz; Annika J Stutz; Nicole Meyer; Kristin Schubert; Isabel Karkossa; Martin von Bergen; Ana C Zenclussen; Anne Schumacher
Journal:  Front Immunol       Date:  2022-09-20       Impact factor: 8.786

6.  CGB5 expression is independently associated with poor overall survival and recurrence-free survival in patients with advanced gastric cancer.

Authors:  Yuxin Yang; Yonghong Shi; Yanjuan Hou; Ying Lu; Jinliang Yang
Journal:  Cancer Med       Date:  2018-02-23       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.